6078:HKEXHygeia Healthcare Holdings Co., Ltd. Analysis
Data as of 2026-06-03 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
Value HR Co.,Ltd. is trading at ¥1,358, which sits below its 20‑day (¥1,378), 50‑day (¥1,421) and 200‑day (¥1,537) simple moving averages, signalling a bearish price momentum. The RSI of 42.5 suggests the stock is not yet oversold, while the MACD line has just edged above its signal line, offering a faint bullish hint that may not be enough to reverse the trend. Volatility is elevated at 28% over the past 30 days, yet the beta is virtually zero (0.01), indicating the price swings are largely company‑specific rather than market‑driven. Fundamental metrics paint a picture of overvaluation: the trailing P/E of 57.8 is more than double the industry average of 27, and the P/B of 5.48 further confirms a premium valuation. Although the dividend yield is 1.99%, the payout ratio exceeds 110% and operating cash flow is zero, raising doubts about dividend sustainability. Leverage is high, with a debt‑to‑equity of 86% and net debt of roughly ¥1.9 bn, while profitability is modest (ROE 9%, operating margin 7.7%). The stock has endured a max drawdown of 28% and faces a near‑term support at ¥1,332 and resistance at ¥1,428. Despite an “Extreme Greed” market sentiment, the combination of technical weakness, lofty multiples, and financial strain suggests caution.
Market Outlook
Short Term
< 1 yearKey Factors
- Price below key moving averages indicating bearish momentum
- Extreme overvaluation relative to industry peers
- Unsustainable dividend payout and zero operating cash flow
Medium Term
1–3 yearsKey Factors
- Increasing trading volume may support a bounce toward resistance
- High leverage and weak cash generation limit upside potential
- Valuation remains stretched despite modest revenue growth
Long Term
> 3 yearsKey Factors
- Aging Japanese population provides secular demand for health‑management services
- Potential upside if the company can deleverage and improve cash flow
- Current valuation premium and financial weaknesses warrant a wait‑and‑see approach
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.